2023

Alzheimer’s disease (AD) is the most common form of dementia; it has no available cure and a 100% fatality rate. The disease starts in the brain many years before the first symptoms occur. Two critical factors in the progression of AD are the vessels in the brain, termed neurovasculature, and the immune system. While the neurovasculature normally forms a tight barrier between the immune system and the brain, this barrier breaks in AD, enabling immune cells to enter the brain. Studies in mice and humans show that this barrier breakdown and AD progression are accelerated by psychosocial stress. In this project, we aim to understand how amyloid beta pathology interacts with the response to stress and its consequences. First, we will compare brain centers that are activated by stress in an amyloid overproduction mouse model and in wild-type control mice using 3-dimensional activity mapping of the whole brain. Second, we will activate these brain centers under relaxed conditions and inhibit them under stressed conditions to understand their individual contributions to AD. We will apply cutting-edge technology, including chemical and light stimulation of specific neurons, to determine whether the stress response can be modulated and what the impact is on amyloid pathology. We envision that highly specific manipulation of distinct brain areas may someday offer new hope for AD patients and their families.

2022

Alzheimer’s disease (AD) is the most common form of dementia; it has no available cure and a 100% fatality rate. The disease starts in the brain many years before the first symptoms occur. Two critical factors in the progression of AD are the vessels in the brain, termed neurovasculature, and the immune system. While the neurovasculature normally forms a tight barrier between the immune system and the brain, this barrier breaks in AD, enabling immune cells to enter the brain. Studies in mice and humans show that this barrier breakdown and AD progression are accelerated by psychosocial stress. In this project, we aim to understand how stress fuels AD, and to identify innovative therapeutic targets to stop this process. First, we will identify brain centers that are activated by stress using 3-dimensional activity mapping of the whole brain. Second, we will activate these brain centers under relaxed conditions and inhibit them under stressed conditions to understand their individual contributions to AD. We will apply cutting-edge technology, including chemical and light stimulation of specific neurons, to identify novel therapies to stop the detrimental effect of stress on AD and to potentially even slow down or reverse AD progression altogether. We envision that highly specific manipulation of distinct brain areas may offer new hope for AD patients and their families.